When hedge fund veteran Martin Shkreli debuted Retrophin, his biotech play, more than few market watchers reacted with healthy skepticism and even open mockery. But now the company’s plans to cash in with a rare-disease treatment have made it a hit with investors, with shares skyrocketing more than 40%.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]